Cargando…

IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells

Chimeric antigen receptor (CAR) redirected T cells are efficacious in the treatment of leukemia/lymphoma, however, showed less capacities in eliminating solid tumors which is thought to be partly due to the lack of cytokine support in the tumor lesion. In order to deliver supportive cytokines, we to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hombach, Andreas A., Geumann, Ulf, Günther, Christine, Hermann, Felix G., Abken, Hinrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226757/ https://www.ncbi.nlm.nih.gov/pubmed/32260097 http://dx.doi.org/10.3390/cells9040873

Ejemplares similares

An Il12-Il2-Antibody Fusion Protein Targeting Hodgkin's Lymphoma Cells Potentiates Activation Of Nk And T Cells For An Anti-Tumor Attack
por: Jahn, Tobias, et al.
Publicado: (2012)

IL12 integrated into the CAR exodomain converts CD8(+) T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors
por: Hombach, Andreas, et al.
Publicado: (2022)

OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells
por: Hombach, Andreas A., et al.
Publicado: (2012)

Young T Cells Age During a Redirected Anti-Tumor Attack: Chimeric Antigen Receptor-Provided Dual Costimulation is Half the Battle
por: Hombach, Andreas A., et al.
Publicado: (2013)

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells
por: Thomas, Simone, et al.
Publicado: (2023)

Most Do, but Some Do Not: CD4(+)CD25(−) T Cells, but Not CD4(+)CD25(+) Treg Cells, Are Cytolytic When Redirected by a Chimeric Antigen Receptor (CAR)
por: Hombach, Andreas A., et al.
Publicado: (2017)

CAR T Cells: A Snapshot on the Growing Options to Design a CAR
por: Holzinger, Astrid, et al.
Publicado: (2019)

Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia
por: Koehler, Philipp, et al.
Publicado: (2012)

Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors
por: Kunert, A., et al.
Publicado: (2017)

Do Treg Speed Up with CARs? Chimeric Antigen Receptor Treg Engineered to Induce Transplant Tolerance
por: Kaljanac, Marcell, et al.
Publicado: (2022)

A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2(+) Solid Cancer
por: Hombach, Andreas A., et al.
Publicado: (2023)

Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells
por: Chmielewski, Markus, et al.
Publicado: (2013)

Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors
por: Abken, Hinrich
Publicado: (2021)

Anti-CD19 CAR T cells potently redirected to kill solid tumor cells
por: Ambrose, Christine, et al.
Publicado: (2021)

GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD(2) and Releasing Inducible IL-18
por: Glienke, Wolfgang, et al.
Publicado: (2022)

CAR's made it to the pancreas
por: Chmielewski, Markus, et al.
Publicado: (2012)

IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation
por: Battram, Anthony M., et al.
Publicado: (2021)

IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Improved Activation toward Primary Colorectal Cancer Cells by Antigen-Specific Targeting Autologous Cytokine-Induced Killer Cells
por: Schlimper, Claudia, et al.
Publicado: (2012)

CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation
por: Barden, Markus, et al.
Publicado: (2023)

The role of MSCs and CAR-MSCs in cellular immunotherapy
por: Yan, Lun, et al.
Publicado: (2023)

Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy
por: Stern, Lawrence A., et al.
Publicado: (2022)

Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells
por: Luo, Hong, et al.
Publicado: (2019)

Targeting two co-operating cytokines efficiently shapes immune responses
por: Hombach, Andreas A., et al.
Publicado: (2013)

Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials
por: Ormhøj, Maria, et al.
Publicado: (2022)

The Human IL-23 Decoy Receptor Inhibits T-Cells Producing IL-17 by Genetically Engineered Mesenchymal Stem Cells
por: Rostami, Masoumeh, et al.
Publicado: (2018)

Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression
por: Lanitis, Evripidis, et al.
Publicado: (2020)

CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine Loop
por: Harrer, Dennis Christoph, et al.
Publicado: (2022)

Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells
por: Harrer, Dennis Christoph, et al.
Publicado: (2022)

Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4(+) T cells to reduce the latent HIV(+) cell reservoir
por: Patasic, Lea, et al.
Publicado: (2020)

Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting
por: Lee, Eric Hee Jun, et al.
Publicado: (2023)

Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors
por: Li, Fanfan, et al.
Publicado: (2022)

Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect in vivo
por: Silvestre, Renata Nacasaki, et al.
Publicado: (2023)

Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma
por: Agliardi, Giulia, et al.
Publicado: (2021)

S80. Prolongation of T cell response by OX40 co-signalling CARS
por: Abken, H
Publicado: (2014)

Antibodies attack IL-17
por: Maxmen, Amy
Publicado: (2010)

A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts
por: Tóth, Gábor, et al.
Publicado: (2020)

Interaction with Mesenchymal Stem Cells Provokes Natural Killer Cells for Enhanced IL-12/IL-18-Induced Interferon-Gamma Secretion
por: Thomas, Heike, et al.
Publicado: (2014)

Engineered IL-7 synergizes with IL-12 immunotherapy to prevent T cell exhaustion and promote memory without exacerbating toxicity
por: Kang, Seounghun, et al.
Publicado: (2023)

Engineered IL-7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer
por: Zhao, Zhenhui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5e76a7v1eh30dd7mla1ot2spsr